Management of Hepatocellular Carcinoma: Updated Review

HTML  XML Download Download as PDF (Size: 218KB)  PP. 536-545  
DOI: 10.4236/jct.2013.42067    6,806 Downloads   10,408 Views  Citations

ABSTRACT

Hepatocellular carcinoma (HCC) represents one of the most challenging potentially curable tumors with high incidence, prevalence and mortality rates. For proper assessment, prognosis estimation and treatment decisions, at least seven important guidelines and staging systems were designated. Proper treatment needs the interaction of multidisciplinary HCC clinic to choose the most appropriate line of treatment. The different modalities of management include resection (surgery or transplantation), local ablation, chemoembolization, radioembolization and molecular targeted therapies with a wide range of investigational drugs that developed after the FDA approved sorafenib. Downstaging and bridging are two important strategies to manage HCC patients who will undergo liver transplantation to improve their postoperative survival. Finally, survival and prognosis depends on several prognostic factors that are either patient related or tumor related. In our study, we aim to provide an updated comprehensive review of the different aspects of liver cancer management starting from staging systems to the different applied treatment modalities.

Share and Cite:

T. Elbaz, M. Kassas and G. Esmat, "Management of Hepatocellular Carcinoma: Updated Review," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 536-545. doi: 10.4236/jct.2013.42067.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.